```
usage: lit [-l LIMIT] [-h] [--export {csv,json,xlsx}]
```

Print latest insider trading. [Source: OpenInsider]

```
optional arguments:
  -l LIMIT, --limit LIMIT
                        Limit of datarows to display (default: 10)
  -h, --help            show this help message (default: False)
  --export {csv,json,xlsx}
                        Export raw data into csv, json, xlsx (default: )
```

Example:

```
2022 Feb 16, 07:58 (ğŸ¦‹) /stocks/ins/ $ lit
                                                                                Insider Data
â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”“
â”ƒ X  â”ƒ Filing Date â”ƒ Trade Date â”ƒ Ticker â”ƒ Company Name      â”ƒ Insider Name         â”ƒ Title      â”ƒ Trade Type   â”ƒ Price  â”ƒ Qty        â”ƒ Owned     â”ƒ Diff Own â”ƒ Value        â”ƒ
â”¡â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”©
â”‚ M  â”‚ 2022-02-16  â”‚ 2022-02-09 â”‚ ZIVO   â”‚ Zivo Bioscience,  â”‚ Maggiore Christopher â”‚ Dir, 10%   â”‚ P - Purchase â”‚ $3.72  â”‚ +91,334    â”‚ 803,105   â”‚ +13%     â”‚ +$340,098    â”‚
â”‚    â”‚ 06:02:09    â”‚            â”‚        â”‚ Inc.              â”‚ D.                   â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-15  â”‚ 2022-02-11 â”‚ RSVR   â”‚ Reservoir Media,  â”‚ Richmond Hill        â”‚ May be     â”‚ P - Purchase â”‚ $6.75  â”‚ +136,364   â”‚ 136,364   â”‚ New      â”‚ +$920,717    â”‚
â”‚    â”‚ 21:57:01    â”‚            â”‚        â”‚ Inc.              â”‚ Investments, LLC     â”‚ deemed a   â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚                   â”‚                      â”‚ 10% owner  â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-15  â”‚ 2022-02-11 â”‚ RSVR   â”‚ Reservoir Media,  â”‚ Richmond Hill        â”‚ May be     â”‚ P - Purchase â”‚ $6.75  â”‚ +58,441    â”‚ 58,441    â”‚ New      â”‚ +$394,588    â”‚
â”‚    â”‚ 21:56:17    â”‚            â”‚        â”‚ Inc.              â”‚ Capital Partners, LP â”‚ deemed a   â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚                   â”‚                      â”‚ 10% owner  â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-15  â”‚ 2022-02-11 â”‚ KNTE   â”‚ Kinnate Biopharma â”‚ Gordon Carl L        â”‚ Dir        â”‚ P - Purchase â”‚ $10.17 â”‚ +195,700   â”‚ 4,043,629 â”‚ +5%      â”‚ +$1,989,446  â”‚
â”‚    â”‚ 21:51:12    â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-15  â”‚ 2022-02-11 â”‚ KNTE   â”‚ Kinnate Biopharma â”‚ Orbimed Advisors LLC â”‚ Dir        â”‚ P - Purchase â”‚ $10.17 â”‚ +195,700   â”‚ 4,043,629 â”‚ +5%      â”‚ +$1,989,446  â”‚
â”‚    â”‚ 21:42:44    â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ DM â”‚ 2022-02-15  â”‚ 2022-02-14 â”‚ RSVR   â”‚ Reservoir Media,  â”‚ Cook Stephen M.      â”‚ Dir        â”‚ P - Purchase â”‚ $7.29  â”‚ +41,510    â”‚ 1,057,171 â”‚ +4%      â”‚ +$302,565    â”‚
â”‚    â”‚ 21:32:18    â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-15  â”‚ 2022-02-14 â”‚ BVS    â”‚ Bioventus Inc.    â”‚ D'Adamio Anthony     â”‚ SVP, GC    â”‚ S - Sale+OE  â”‚ $11.99 â”‚ -1,294     â”‚ 18,672    â”‚ -6%      â”‚ -$15,513     â”‚
â”‚    â”‚ 21:31:03    â”‚            â”‚        â”‚                   â”‚                      â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ DM â”‚ 2022-02-15  â”‚ 2022-02-11 â”‚ AREN   â”‚ Arena Group       â”‚ B. Riley Financial,  â”‚ 10%        â”‚ P - Purchase â”‚ $8.26  â”‚ +1,977,982 â”‚ 5,411,514 â”‚ +58%     â”‚ +$16,329,921 â”‚
â”‚    â”‚ 21:30:53    â”‚            â”‚        â”‚ Holdings, Inc.    â”‚ Inc.                 â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-15  â”‚ 2022-02-14 â”‚ BVS    â”‚ Bioventus Inc.    â”‚ Anglum Gregory O.    â”‚ SVP, CFO   â”‚ S - Sale+OE  â”‚ $11.99 â”‚ -1,294     â”‚ 55,013    â”‚ -2%      â”‚ -$15,518     â”‚
â”‚    â”‚ 21:27:43    â”‚            â”‚        â”‚                   â”‚                      â”‚            â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-15  â”‚ 2022-02-14 â”‚ BVS    â”‚ Bioventus Inc.    â”‚ Nosenzo John         â”‚ Chief      â”‚ S - Sale+OE  â”‚ $11.99 â”‚ -534       â”‚ 43,370    â”‚ -1%      â”‚ -$6,401      â”‚
â”‚    â”‚ 21:17:44    â”‚            â”‚        â”‚                   â”‚                      â”‚ Commercial â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚                   â”‚                      â”‚ Officer    â”‚              â”‚        â”‚            â”‚           â”‚          â”‚              â”‚
â””â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
D: Derivative transaction in filing (usually option exercise)
M: Multiple transactions in filing; earliest reported transaction date & weighted average transaction price
```
